In this study, we found that the EZH2 inhibitor, DZNeP, promotes the effect of the BCL-2 inhibitor, Ven, on cell growth arrest and apoptosis in AML cell lines and in primary leukemic cells from AML patients in a PIK3IP1-dependent manner. This evidence concerns the gene BCL2 and acute myeloid leukemia.